Sanofi in discussions to sell a controlling stake in Opella

Sanofi has entered into negotiations with CD&R for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business.

[Read more: U.S. News & World Report reveals the 2024 Best OTC Medicine & Health Products]

Further updates on the potential separation of Opella will be provided in due course, when a decision is made.

Headquartered in France, Opella employs over 11,000 people, operates in 100 countries and manages 13 best-in-class manufacturing sites and four research and innovation centers. With a portfolio of 100 leading brands, including Allegra, Doliprane, Novanight, Icy Hot and Dulcolax, Opella is the world's third-largest company in the over the counter and vitamins, minerals and supplements market, serving more than half a billion consumers worldwide.

[Read more: A Force for Change: Sanofi Consumer Healthcare North America is B Corp Certified]